Karyopharm Therapeutics (KPTI) Accounts Payables (2012 - 2025)

Karyopharm Therapeutics has reported Accounts Payables for 14 years, with the latest figure at $4.0 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 21.62% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2025 stood at $4.0 million (down 21.62% YoY), and the FY2025 full-year result was $4.0 million, down 21.62% from the prior year.
• Accounts Payables for Q4 2025 stood at $4.0 million, down from $5.4 million in the prior quarter.
• The five-year high for Accounts Payables was $9.0 million in Q1 2023, with the low at $813000.0 in Q3 2022.
• Historically, Accounts Payables has averaged $3.4 million across 5 years, with a median of $2.9 million in 2021.
• Annual changes were most pronounced in 2021 — Accounts Payables plunged 63.98% — and 2024, when it surged 513.26%.
• Karyopharm Therapeutics' Accounts Payables stood at $1.6 million in 2021, then soared by 72.99% to $2.8 million in 2022, then grew by 12.62% to $3.1 million in 2023, then soared by 63.53% to $5.1 million in 2024, then retreated by 21.62% to $4.0 million in 2025.
• The last three Accounts Payables figures came in at $4.0 million (Q4 2025), $5.4 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.